Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Lice Treatment Market

Lice Treatment Market Trends

Report ID: GMI9176
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Lice Treatment Market Trends

The growth of the market is significantly propelled by the easy availability of lice treatment products, which are accessible through various retail channels such as pharmacies, supermarkets, and online platforms. This widespread availability ensures that individuals can quickly and conveniently obtain treatment options when faced with lice infestations.
Further, with over the counter (OTC) drugs and products readily accessible without the need for a prescription, consumers are empowered to initiate treatment promptly at the first indication of an infestation. This timely intervention is crucial for effectively managing lice infestations and preventing their spread to others, thereby augmenting the market expansion.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Lice treatment industry size recorded USD 1 billion in 2023 and is expected to register 6.5% CAGR from 2024 to 2032, due to the rising prevalence of lice infestations.

The OTC products segment in the market accounted for 62.6% share in 2023 and is projected to witness substantial growth from 2024 to 2032, on account of the rising environmental concerns along with consumer demand for non-toxic, eco-friendly products.

North America lice treatment industry accumulated USD 461.5 million in revenue in 2023 and is expected to expand at 6.4% CAGR from 2024 to 2032, due to the presence of a larger infestation pool and the increasing children population in the region.

Alliance Pharma PLC, Azurity Pharmaceuticals, Inc., Fleming Medical Ltd., Oystershell Consumer Health, Parapro Pharmaceuticals, Perrigo Company plc, Prestige Consumer Healthcare Inc., Reckitt Benckiser Group plc, Sanofi S.A., and Thornton & Ross Ltd.